Galindo Alejandro
Known title: Chief Commercial OfficerCIK: 0001821447
Galindo Alejandro's purchase track record
How the stock did after each of Galindo Alejandro's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since January 31, 2022
Stock higher 6 months later
67%
3 months: 33%
Median 6-month return
+37.8%
3 months: -5.6%
Beat the S&P 500
100%
median +45.6% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/31/2022 | MNKD | $15K | -5.6% | +43.9% | -2.5% |
| 2/28/2022 | MNKD | $100K | +59.5% | +37.8% | -7.8% |
| 1/31/2022 | MNKD | $7K | -12.1% | -4.0% | -8.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MNKD | ▼ Sell | Open Market | 15 | $58 | 8/22/2022 | View on chart |
| MNKD | ▼ Sell | Open Market | 4,600 | $18K | 8/22/2022 | View on chart |
| MNKD | ▲ Buy | Open Market | 5,000 | $15K | 7/31/2022 | View on chart |
| MNKD | ▼ Sell | Tax Withholding | 4,789 | $15K | 5/18/2022 | View on chart |
| MNKD | ▲ Buy | Grant | 90,000 | $0 | 5/10/2022 | View on chart |
| MNKD | ▲ Buy | Grant | 110,000 | $0 | 5/10/2022 | View on chart |
| MNKD | ▲ Buy | Open Market | 36,900 | $100K | 2/28/2022 | View on chart |
| MNKD | ▲ Buy | Open Market | 2,334 | $7K | 1/31/2022 | View on chart |
| MNKD | ▼ Sell | Tax Withholding | 9,616 | $47K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
MannKind Presents Furoscix Data at HFSA 2026
MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.
MannKind Presents Furoscix Data at HFSA 2026. MannKind reported new data at the HFSA 2026 conference showing that its Furoscix ReadyFlow autoinjector produced urine output comparable to IV furosemide. The study supports the use of the device for managing edema in patients with heart failure and chronic kidney disease. Truist Securities maintained its rating on the stock but lowered its price target to $5.